Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Impacted Canine and Mixed-reality Technology - RCT

NCT06574477 · tracked via the Priya Life Science Poland tracker
Sponsor
Piotr Fudalej
Phase
Not applicable
Started
2021-10-01
Last updated
2024-08-28

Condition(s) studied

Tooth, Impacted

Investigational drug(s) / intervention(s)

Planning of alignment with HoloLens 2No planning of alignment with HoloLens 2

Planning of alignment with HoloLens 2: Planning of attachment position and traction direction with HoloLens 2 goggles

No planning of alignment with HoloLens 2: No planning of attachment position and traction direction with HoloLens 2 goggles

Study summary

The goal of this clinical trial is to determine whether the use of HoloLens 2 mixed reality goggles for planning alignment of palatally impacted canine reduces: 1) treatment time and 2) the risk of complications compared to planning alignment of palatally impacted canine without HoloLens 2 goggles.

Participants will have an impacted canine on palatal side.

Researchers will use or will not use HoloLens 2 goggles in planning therapy

Participants will wear fixed orthodontic appliances for the treatment of impacted canine. During treatment, attachment will fixed to an impacted canine and the direction of traction will be established.

Eligibility

Sex
ALL
Min age
10 Years
Max age
20 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy boys/men and girls/women aged between 10 and 20 years. * Palatally impacted canine on one side * Axis of the canine \> 10 degrees to the midline as measured on a pantomographic radiograph * During orthodontic treatment, in preparation for alignment of the impacted canine with adequate space for the retained canine Exclusion Criteria: * Dental abnormalities (hyperodontia, hypodontia, etc.) * Impacted canines bilaterally * Previous trauma to the teeth or face * Congenital craniofacial malformations * Systemic diseases that would hinder orthodontic treatment/operation * Recent radiotherapy

Primary outcome measure(s)

  • Alignment duration — 6 months, 12 months
    total duration of the phase of the alignment of impacted canine (in days)

Trial sites (1)

FacilityCityRegionStatus
Jagiellonian University Medical College Krakow Poland Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06574477 on ClinicalTrials.gov ↗ ← All trials in Poland